Deborah Hood
Adult Health · Jackson, MSNPI 1922565738
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,388 and has fallen 67.6% since, to $450 in 2025.
Across 297 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$638
- AbbVie$616
- Bayer$498
- Pfizer$435
- Lilly USA, LLC$294
- Dexcom, Inc.$258
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $638 |
| AbbVie | 55 | $616 |
| Bayer | 34 | $498 |
| Pfizer | 31 | $435 |
| Lilly USA, LLC | 21 | $294 |
| Dexcom, Inc. | 13 | $258 |
| GSK | 15 | $215 |
| Abbott | 8 | $174 |
| AstraZeneca(2 entities) | 8 | $160 |
| Otsuka America Pharmaceutical, Inc. | 4 | $115 |
| Eisai Inc. | 7 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Boehringer Ingelheim | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Exact Sciences | 5 | $69 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Amgen | 3 | $56 |
| Lundbeck LLC | 2 | $55 |
| Genentech USA, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Merck | 2 | $33 |
| Shield Therapeutics Inc | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Ardelyx, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Medtronic | 1 | $13 |
How this compares
$4,348 in reported general payments places this provider in the 85th percentile of 93 adult health providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 47 | $55,489 |
| MounjaroTirzepatide | 28 | $32,917 |
| EliquisApixaban | 29 | $31,914 |
| XareltoRivaroxaban | 18 | $20,255 |
| JardianceEmpagliflozin | 16 | $18,516 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,974 |
| GemtesaVibegron | 13 | $9,685 |
| FarxigaDapagliflozin Propanediol | 11 | $9,534 |
| Rosuvastatin Calcium | 192 | $3,471 |
| SynthroidLevothyroxine Sodium | 35 | $3,456 |
| Atorvastatin Calcium | 183 | $2,699 |
| Levothyroxine Sodium | 189 | $2,505 |
| Bupropion XlBupropion Hcl | 63 | $2,107 |
| Losartan Potassium | 143 | $2,027 |
| Pantoprazole Sodium | 150 | $1,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $638 | $55,48947 claims |
| Lilly USA, LLCMounjaro | $294 | $32,91728 claims |
| PfizerEliquis | $435 | $31,91429 claims |
| Boehringer IngelheimJardiance | $82 | $18,51616 claims |
| GSKTrelegy Ellipta | $215 | $9,97416 claims |
| AstraZenecaFarxiga | $160 | $9,53411 claims |
| AbbVieSynthroid | $616 | $3,45635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 adult health providers in Mississippi.
Other adult health in Jackson
- Keila BrownJackson$7K
- Brandi JohnstonJackson$7K
- Ashley FitzhughJackson$4K
- Frances WoodwardJackson$3K
- Candice ColemanJackson$3K
- Nina WaltzerJackson$1K
- Gretchen ShullJackson$818
- Janice HuffJackson$585
- Chatina MartinJackson$478
- Gwendolyn McAlpineJackson$425
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.